These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

33 related articles for article (PubMed ID: 11307812)

  • 1. Absence of circulating factor IX antigen in hemophilia B dogs of the UNC-Chapel Hill colony.
    Herzog RW; Arruda VR; Fisher TH; Read MS; Nichols TC; High KA
    Thromb Haemost; 2000 Aug; 84(2):352-4. PubMed ID: 10959714
    [No Abstract]   [Full Text] [Related]  

  • 2. Lessons Learned from Animal Models of Inherited Bleeding Disorders.
    Nichols TC
    Hematol Educ; 2014 Jun; 8(1):39-46. PubMed ID: 26052366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Portal vein delivery of viral vectors for gene therapy for hemophilia.
    Sherman A; Schlachterman A; Cooper M; Merricks EP; Raymer RA; Bellinger DA; Herzog RW; Nichols TC
    Methods Mol Biol; 2014; 1114():413-26. PubMed ID: 24557919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell-based multiscale computational modeling of small molecule absorption and retention in the lungs.
    Yu JY; Rosania GR
    Pharm Res; 2010 Mar; 27(3):457-67. PubMed ID: 20099073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency.
    Nichols TC; Dillow AM; Franck HW; Merricks EP; Raymer RA; Bellinger DA; Arruda VR; High KA
    ILAR J; 2009; 50(2):144-67. PubMed ID: 19293459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Haemophilic factors produced by transgenic livestock: abundance that can enable alternative therapies worldwide.
    Van Cott KE; Monahan PE; Nichols TC; Velander WH
    Haemophilia; 2004 Oct; 10 Suppl 4(0 4):70-6. PubMed ID: 15479375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant factor IX.
    White GC; Beebe A; Nielsen B
    Thromb Haemost; 1997 Jul; 78(1):261-5. PubMed ID: 9198163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitor antibodies to factor VIII and factor IX: management.
    Lusher JM
    Semin Thromb Hemost; 2000; 26(2):179-88. PubMed ID: 10919411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of recombinant factor IX after intravenous and subcutaneous administration in dogs and cynomolgus monkeys.
    McCarthy K; Stewart P; Sigman J; Read M; Keith JC; Brinkhous KM; Nichols TC; Schaub RG
    Thromb Haemost; 2002 May; 87(5):824-30. PubMed ID: 12038784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extravascular administration of factor IX: potential for replacement therapy of canine and human hemophilia B.
    Liles D; Landen CN; Monroe DM; Lindley CM; Read MS; Roberts HR; Brinkhous KM
    Thromb Haemost; 1997 May; 77(5):944-8. PubMed ID: 9184407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Head-to-head comparison of the pharmacokinetic profiles of a high-purity factor IX concentrate (AlphaNine®) and a recombinant factor IX (BeneFIX®) in patients with severe haemophilia B.
    Lissitchkov T; Matysiak M; Zavilska K; Laguna P; Gercheva L; Antonov A; Moret A; Caunedo P; Aznar JA; Woodward MK; Páez A
    Haemophilia; 2013 Sep; 19(5):674-8. PubMed ID: 23647607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of recombinant human factor IX: pharmacokinetic studies in the rat and the dog.
    Keith JC; Ferranti TJ; Misra B; Frederick T; Rup B; McCarthy K; Faulkner R; Bush L; Schaub RG
    Thromb Haemost; 1995 Jan; 73(1):101-5. PubMed ID: 7740479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced bleeding events with subcutaneous administration of recombinant human factor IX in immune-tolerant hemophilia B dogs.
    Russell KE; Olsen EH; Raymer RA; Merricks EP; Bellinger DA; Read MS; Rup BJ; Keith JC; McCarthy KP; Schaub RG; Nichols TC
    Blood; 2003 Dec; 102(13):4393-8. PubMed ID: 12933577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intratracheal administration of recombinant human factor IX (BeneFix) achieves therapeutic levels in hemophilia B dogs.
    Russell KE; Read MS; Bellinger DA; Leitermann K; Rup BJ; McCarthy KP; Keith JC; Khor SP; Schaub RG; Nichols TC
    Thromb Haemost; 2001 Mar; 85(3):445-9. PubMed ID: 11307812
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.